PreclinicalShort bioregulator peptide

Ovagen

Glu-Asp-Leu (EDL), T-35

Common dose: ~1–2 mg daily for 10–30 days
Cycle: 3-week course, about every 5 months
Vial sizes: 20 mg
Typical draw: 10 units20 mg with 2 mL, 1 mg

A synthetic three-amino-acid peptide from the Russian bioregulator family, sold for liver and digestive support. Its published studies, in rat kidneys and kidney cell cultures, reported kidney-protective effects.

Evidence. Cell, tissue-culture and rat studies only, nearly all from Khavinson’s St Petersburg institute and a partner lab in Ukraine, in Russian journals. Though sold for the liver, the published studies of this peptide are on kidneys; no study has given it to people.

What it’s used for

None of these uses is approved, and none has been tested in people. Here is what each claim rests on.

Liver protection and liver fibrosis: No studyUnproven: it’s sold for the liver, and its developers’ 2021 review lists liver protection, but no liver study of this peptide appears in PubMed, in animals or people.
Acute kidney injury: AnimalIn rats with kidney injury from cisplatin, gentamicin or cut-off blood flow (2015 and 2017 studies by the developers and a Ukrainian partner lab), it limited the loss of kidney function. Not tested in people.
Kidney aging: AnimalIn developer studies (2014–2018) of kidney cell and tissue cultures, including old-rat tissue, it raised cell renewal and lowered aging markers; in old rats it increased urine output. Unproven in people.
Gut lining and digestion: No studyGuides claim it protects the gut lining and aids digestion. No published study has tested this in animals or people.

Animal: cell or animal studies only. No study: nothing published supports it.

Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.

Status

Approval: Not approved as a drug in the US or EU. In Russia it’s sold as oral capsules marketed as a dietary supplement, not as a medicine.
US compounding: Not nominated for US compounding: it isn’t on FDA’s 503A (May 2026) or 503B (March 2025) bulk substance nomination lists.
European Union: No marketing authorization; no medicine containing this peptide is approved anywhere.
United Kingdom: No marketing authorization (MHRA).
Canada: No marketing authorization. The OVAGEN in Health Canada’s Drug Product Database is an unrelated veterinary fertility hormone.
Australia: No marketing authorization. Ovagen isn’t named in the Poisons Standard (October 2026).
Sport (WADA 2026): Likely banned in sportNot named on WADA’s 2026 list. A supplement sale isn’t an approval for human therapeutic use, so its S0 rule for non-approved substances likely applies, at all times.

Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.

How it works

No receptor or target is known. Its developers propose that this three-amino-acid peptide enters cells and binds DNA, changing which genes are read; that idea comes from computer modeling. In the developers’ 2014 studies of aging kidney cell cultures it raised cell division and SIRT-6, a protein linked to cell aging, and lowered the aging markers p16, p21 and p53. In rats with drug-induced or blood-flow kidney injury, it limited the loss of kidney function and curbed oxidative damage.

AnimalMainly from cell and animal studies; not shown in people.

Not known

Its target is unknown, no liver study exists despite its marketing, and whether it survives digestion or injection, or helps people’s kidneys or liver, is untested.

Protocol

Community

Injected: 1–2 mg once daily for 10–30 days is where guides overlap; across all guides, amounts differ more than 1,000-fold. None was tested in people.

Community

By mouth: guides list 10–50 mg a day for 10–20 days, and Russian supplement capsules are sold. No human study has tested either.

Frequency: Once daily during a course
Route: Subcutaneous injection or capsules by mouth (community)
Cycle: 10–30 day courses, 1–3 times a year.
3-week course, about every 5 months, shown over 26 weeks

Common protocols

The ways Ovagen is most often run, each tagged with where it comes from.

Injected course

Community

Dose: 1–2 mg
How often: Once daily
How long: 10–30 days

Where guides overlap; some run 30–60 days, once or twice a year. No dose has been tested in people.

Draw 10–20 units20 mg + 2 mL

Oral course

Community

Dose: 10–50 mg, or Russian supplement capsules
How often: Once daily
How long: 10–20 days

Guides repeat courses 2–3 times a year. No human study has used the capsules or any oral amount.

Taking it

Where it goes

Subcutaneous, rotating between the abdomen, thigh and upper arm; capsules are swallowed. Published research used rats and kidney cell cultures, not people.

If you miss a dose

No published guidance. Resume the next day and don’t double up.

Missed doses for every compound

What to expect

During a course
Guides claim liver and digestive support. No human study has measured any effect.
Community
Days to weeks (rats)
In rats with drug-induced or blood-flow kidney injury, it limited the drop in urine output and the buildup of waste products in the blood.
Animal

Side effects and what to do

Injection-site redness or swelling

Usually mild; rotate sites. Spreading redness, heat or pus means see a doctor.

No side-effect data from people

No study has given it to anyone, so side effects and their rates are unknown.

Allergic reaction (possible with any injected peptide)

Stop and get emergency care for hives, facial swelling or trouble breathing.

Stop and get medical help

Stop and get medical help for hives, swelling of the face or throat, trouble breathing, or a hot, spreading or pus-filled injection site.

Can it cause …?

There are almost no human safety data for Ovagen, so most of these can’t be answered either way.

Liver strain: No dataNo human data. It’s sold for the liver, but no study has checked liver tests in anyone taking it.
Kidney problems: No dataNo human data. In rats it protected injured kidneys, and its developers saw no kidney damage in old rats.
Cancer risk: PrecautionUnknown. In kidney cell cultures it raised cell division and lowered p53, a brake on cell growth; no study has tested its effect on tumors.
TirednessHeadacheNausea or vomitingDiarrhea or constipationDizzinessTrouble sleepingHair lossAcne, rash or skin changesWater retention or swellingJoint or muscle painAnxiety, low mood or irritabilityLow or high blood sugarFast heartbeat or blood pressure changesMore hunger: No dataNo human data: no study of Ovagen in people has been published, so side effects are unknown.

Precaution: a concern that follows from how it works or from a related drug, not measured. No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.

Who should avoid it

No product label covers Ovagen, so these come from human studies and from precautions based on how it works. Most important first.

Anyone with active or past cancer: PrecautionIn kidney cell cultures it raised cell division and lowered p53, a brake on cell growth. No study has tested its effect on tumors.
Pregnancy or breastfeeding: PrecautionNo human safety data exist.
Liver or kidney disease: PrecautionSold for the liver and studied in rat kidneys, but never tested in anyone with liver or kidney disease.
Anyone relying on product quality: PrecautionVials have no regulated standard for identity, purity or sterility, supplement capsules aren’t checked like medicines, and unrelated products share the name.

Interactions

No interaction studies have been published, and no product label lists any.

Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.

Special situations

What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.

Pregnancy: PrecautionNo human or animal pregnancy data, so effects on a pregnancy are unknown.
Breastfeeding: PrecautionNo human data; it isn’t known whether it passes into breast milk.
Kidney problems: PrecautionNot studied in people with kidney disease. Rat studies suggest kidney protection, but how the body clears it is unknown.
Liver problems: PrecautionSold for the liver, but never tested in people with liver disease, and no liver study of it exists in animals either.
Older adults: PrecautionNo study has given it to older people. In old rats it increased urine output and sodium loss, with no sign of kidney damage.
Children and teens: PrecautionNot studied in anyone under 18, and not approved for any age.
Surgery and anesthesia: PrecautionNo data; tell the surgical team about any injected compound.

Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.

Tracking and pairing

Worth tracking

No established labs or checks.

Often paired with

Livagen
Some guides pair the two liver-marketed peptides. No study has tested them together.

Human studies

No published human studies of Ovagen turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

Trials under way

No ongoing trial of Ovagen is registered, and none has finished recently without publishing its results. Checked on ClinicalTrials.gov, October 7, 2026. Every compound: trials under way.

Limits of the evidence

No study has given Ovagen to people. The published work on its peptide, EDL, is kidney cell and tissue cultures and rat models of kidney injury and aging, from Khavinson’s St Petersburg institute and a partner lab in Ukraine, in Russian journals. Nothing published tests the liver or gut uses it’s sold for. Oral and injected doses, long-term safety and product purity are untested.

Mixing your vial

Vial	Water	Common dose	Draw	Strength	Action
20 mg	2 mL	1 mg	10 units (0.10 mL)	10 mg/mL

20 mg in 2 mL gives 10 mg per mL, so 1 mg is 10 units on a U-100 syringe. In Russia it’s also sold as oral capsules, which need no mixing. Check that the certificate of analysis shows EDL: Livagen (KEDA) is a different peptide.

Dose chart

20 mg vial

Syringe units for common doses at different water volumes. Select a cell to open it in the calculator.

Dose	Water added
Dose	1 mL	2 mL	3 mL
0.1 mg
0.25 mg
0.5 mg
1 mg
2.5 mg
5 mg
10 mg

U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.

Datasheet

Half-life: No reliable value has been published.
Type: Peptide, 3 amino acids
Molecular weight: 375.4 g/mol
Formula: C₁₅H₂₅N₃O₈
Sequence: EDL
Storage before use: Freezer (about −20 °C) for long-term storage.
After mixing or opening: Fridge (2–8 °C); use within about 4 weeks.

Molecule: PubChem CID 444128 (Glu-Asp-Leu); named Ovagen in Khavinson et al., Molecules 2021
Storage: Community Common practice for research peptides; no approved label exists.

Every compound side by side: the half-life chart and the storage chart.

Identifiers

UNII (FDA): None assigned
PubChem CID: 444128
ATC code: None assigned
Development codes: None; also written EDL (Glu-Asp-Leu); called T-35 in some lab studies
Brand names: None as a medicine; Ovagen is the name of Russian supplement capsules
First described: From Khavinson’s St Petersburg group; the earliest PubMed records of EDL, coded T-35, date from 2014.

Every compound’s numbers: the identifiers table.

Product form and quality

A three-amino-acid peptide, Glu-Asp-Leu (EDL), sold as Russian supplement capsules and as research vials. Livagen (KEDA) is a different liver-marketed peptide. The name Ovagen also belongs to a veterinary fertility hormone (sheep FSH) and a US homeopathic remedy.

Cautions

No study has given Ovagen to people, so there are no human safety or dosing data.
Sold for the liver, but its published studies are on rat kidneys and kidney cells.
Guide doses differ more than 1,000-fold.
The name also belongs to unrelated products, including a veterinary fertility hormone.

Questions

What is Ovagen?

How does Ovagen work?

Is Ovagen FDA-approved?

Not approved as a drug in the US or EU. In Russia it’s sold as oral capsules marketed as a dietary supplement, not as a medicine. Not nominated for US compounding: it isn’t on FDA’s 503A (May 2026) or 503B (March 2025) bulk substance nomination lists.

What is the usual Ovagen dose?

From community reports, not established: Injected: 1–2 mg once daily for 10–30 days is where guides overlap; across all guides, amounts differ more than 1,000-fold. None was tested in people. By mouth: guides list 10–50 mg a day for 10–20 days, and Russian supplement capsules are sold. No human study has tested either. These are the amounts sources reference, not recommendations.

How much water do I mix Ovagen with?

There’s no single right amount, because the water only sets the strength. With 2 mL of bacteriostatic water in a 20 mg vial, the strength is 10 mg/mL, so 1 mg is 10 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.

Who should avoid Ovagen?

No product label covers Ovagen, so these come from human studies and from precautions based on how it works. Anyone with active or past cancer: In kidney cell cultures it raised cell division and lowered p53, a brake on cell growth. No study has tested its effect on tumors. Pregnancy or breastfeeding: No human safety data exist. Liver or kidney disease: Sold for the liver and studied in rat kidneys, but never tested in anyone with liver or kidney disease. The “Who should avoid it” section lists 1 more group.

How should Ovagen be stored?

Before mixing: Freezer (about −20 °C) for long-term storage. After mixing: Fridge (2–8 °C); use within about 4 weeks. This is common practice; no product label covers it.

Is Ovagen banned in sport?

Probably. Not named on WADA’s 2026 list. A supplement sale isn’t an approval for human therapeutic use, so its S0 rule for non-approved substances likely applies, at all times.

Has Ovagen been studied in people?

No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

How long has Ovagen been studied in people?

No data No human studies: no study of Ovagen (EDL) in people has been published.

Does Ovagen come in other forms, like a pill or nasal spray?

No data No human data for any route. In Russia it’s sold as capsules to swallow, and research vials are injected under the skin; neither route has been studied in people.

Can you drink alcohol while taking Ovagen?

No study No data. No study has looked at Ovagen and alcohol together, or at alcohol-related liver damage.

Can Ovagen be taken with semaglutide or tirzepatide?

No study No study has combined them. No interaction is known, but none has been looked for.

What happens if you take too much Ovagen?

No data There’s no label, no overdose data and no human dosing study. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.

Sources

Khavinson et al., review of peptide regulation of gene expression, naming Glu-Asp-Leu as Ovagen (Molecules 2021) PMID 34834147
Zamorskii et al., EDL peptide in rats with acute kidney injury (Bull Exp Biol Med 2017) PMID 28744634
Khavinson et al., AED and EDL in aging kidney cell cultures (Adv Gerontol 2014, in Russian) PMID 25946838

For the protocol details

Zamorskii et al., peptides including EDL in rats with cisplatin-induced kidney failure (Bull Exp Biol Med 2015) PMID 26515176

For how it works, who should avoid it and the limits of the evidence

Khavinson et al., calf-kidney peptides, AED and EDL (T-35) in aging kidney cell cultures (Bull Exp Biol Med 2014) PMID 24958378
Zamorskii et al., peptides including EDL and kidney function in old rats (Adv Gerontol 2018, in Russian) PMID 30607912
Khavinson et al., computer models of short peptides binding DNA (Bull Exp Biol Med 2016) PMID 27909961

For uses, the side-effect questions, special situations, trials, identifiers and status outside the US

Chalisova et al., peptides and cell renewal in kidney tissue cultures from young and old rats (Bull Exp Biol Med 2015) PMID 26033601
ClinicalTrials.gov search for Ovagen (October 8, 2026)
FDA Global Substance Registration System search (no record) and PubChem CID 444128
Health Canada Drug Product Database, OVAGEN (DIN 02337673, ovine FSH, veterinary), searched October 8, 2026
DailyMed listing for R18 Ovagen, a homeopathic product (published January 10, 2024)
Australian Poisons Standard, October 2026 (F2026L01327)

Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.

By Vial Guide editorsLast reviewed October 7, 2026

How we review